Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
Mineralys Therapeutics announced a $200 million upfront payment plus up to $100 million in milestones to Tanabe Pharma to repurchase all future royalty obligations on its lead asset, lorundrostat. To fund this transaction and strengthen its balance sheet, the company secured a $500 million senior secured term loan from Pharmakon Advisors, with $100 million available at closing and the remainder in tranches through June 2031. Concurrently, Mineralys priced a $150 million public offering of common stock.
Key figures
- Shares Offered
- approximately $150.0 million of its shares
- Debt maturity
- June 2031
- Debt interest rate
- SOFR + 5.50% (SOFR floor 3.25%)
- Debt facility total
- 500000000
- Royalty buyout upfront
- 200000000
- Royalty buyout milestones
- 100000000
- Debt facility initial draw
- 100000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.